Answers are grounded in this paper and cite their sources.
Observational analysis supports early detection of cancer using liquid biopsy in oncology, suggesting improved patient outcomes.
Background: Despite being the gold standard for molecular profiling and cancer diagnosis, traditional tissue biopsy has drawbacks such as invasiveness, procedural hazards, and difficulties capturing tumor heterogeneity. A minimally invasive method for thorough tumor profiling, liquid biopsy is based on the examination of circulating tumor DNA (ctDNA), circulating tumor cells (CTCs), and other indicators in blood or bodily fluids. Clinical use has accelerated due to regulatory approvals of ctDNA-based tests including FoundationOne Liquid CDx and Guardant360 CDx, and ongoing trials are investigating its potential for minimal residual disease (MRD) surveillance and early identification.
No takes yet. Share an insight, caveat, or question.
Goswami et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: